Thursday, January 18, 2018 2:09:23 AM
Your post referred to the overall data, including Fast and Slow progressors, where statistical efficacy was shown for 2 weeks.
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/0_aey9hdpc/def_height/400/def_width/400/version/100012/type/1
But for the Phase III trial, Brainstorm stated they are only going to be recruiting Fast Progressors. These had 4 weeks statistical benefit
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/0_r883qntw/def_height/400/def_width/400/version/100012/type/1
Brainstorm saw this and so is using only the fast progressors only for the Phase III to maximise the chances of Phase III success.
Also what you need to understand is that the '100% Improvement' in the ALSFRS-R slope effectively means no worsening of the situation or even potential improvement. So this means that in these Fast Progressors, NurOwn appears to be stopping the disease progression in it's tracks.
Also, clearly a treatment that would require a once every 2 weeks injection of new cells would not be seen as convenient or maybe even economically possible for patients. Thus also the benefit of the efficacy lasting 4 weeks. A nice once a month injection to potentially stop ALS dead in it's track in these fast progressors. That indeed will be a very fortunate treatment for these patients.
Recent BCLI News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/30/2024 04:15:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 08:30:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/24/2024 08:30:50 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/17/2024 07:32:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:36:41 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/28/2024 09:01:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/16/2024 11:00:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:21 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 08/06/2024 08:59:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/05/2024 09:11:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:18 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (Canada) • 07/24/2024 12:30:00 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (US) • 07/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:57 PM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM